Shares of Sanofi (NYSE:SNY) saw unusually-strong trading volume on Tuesday . Approximately 7,489,941 shares were traded during mid-day trading, an increase of 14% from the previous session’s volume of 6,589,197 shares.The stock last traded at $41.78 and had previously closed at $41.42.

A number of equities analysts recently commented on the stock. Barclays PLC raised shares of Sanofi from an “equal weight” rating to an “overweight” rating in a research report on Thursday, May 12th. Chardan Capital reaffirmed a “buy” rating on shares of Sanofi in a research report on Tuesday, April 12th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Wednesday, May 4th. Goldman Sachs Group Inc. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, March 18th. Finally, JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Sanofi in a research report on Monday, April 25th. Four analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $49.67.

The company has a market cap of $108.03 billion and a P/E ratio of 22.89. The firm’s 50 day moving average price is $40.53 and its 200-day moving average price is $40.73.

Several institutional investors recently modified their holdings of SNY. Rhumbline Advisers increased its position in shares of Sanofi by 7.3% in the fourth quarter. Rhumbline Advisers now owns 26,510 shares of the company’s stock worth $1,131,000 after buying an additional 1,800 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Sanofi by 1.7% in the fourth quarter. Ameritas Investment Partners Inc. now owns 37,113 shares of the company’s stock worth $1,582,000 after buying an additional 613 shares during the period. Pinnacle Associates Ltd. increased its position in shares of Sanofi by 2.2% in the fourth quarter. Pinnacle Associates Ltd. now owns 37,682 shares of the company’s stock worth $1,607,000 after buying an additional 805 shares during the period. Freestone Capital Holdings LLC bought a new position in shares of Sanofi during the fourth quarter worth $1,672,000. Finally, Stephens Inc. AR increased its position in shares of Sanofi by 4.5% in the fourth quarter. Stephens Inc. AR now owns 56,811 shares of the company’s stock worth $2,423,000 after buying an additional 2,424 shares during the period.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.